The absorption of neffy may be affected in patients with underlying structural or anatomical nasal conditions (eg, nasal polyps, history of nasal surgery). In these patients, epinephrine products ...
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and ...
The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...
Regeneron Pharmaceuticals and Sanofi have received Food and Drug Administration approval for their treatment of an inflammatory condition that affects the sinuses and nasal passages in adolescents, ...